The most current information regarding Rezulin liver-related deaths and transplants released by the company covers the period through March 5. As of that date, Rezulin therapy was possibly or probably associated with 28 liver-related deaths, seven liver transplants and eight cases of encephalopathy. The May 31 issue of "The Pink Sheet" (p. 4) implied that those numbers remain unchanged. However, the company continues to evaluate information on Rezulin and has not publicly updated those figures
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth